No Effect on Manufacture, Export, Supply or Sale of Jeuveau® or Nuceiva®
Settlement Agreement with Medytox Provided for Continued Manufacturing and Commercialization for Evolus Regardless of Any Litigation Between Medytox and Daewoong
RBC Capital Maintains Outperform on Gildan Activewear, Lowers Price Target to $47
RBC Capital analyst Sabahat Khan maintains Gildan Activewear (NYSE:GIL) with a Outperform and lowers the price target from $52 to $47.
